Midatech Pharma PLC (LON:MTPH) has started to dose patients in its phase 1 study of MTD201, a possible new treatment for hormonal-based cancers such as acromegaly and neuroendocrine tumours (NET).
The first cohort of healthy volunteers, 14 out of 28 subjects, received one dose of Sandostatin 100 microgram/1 ml solution on 5 October, which has been followed by a 30mg injection of MTD201.
The remaining 14 subjects will undergo the same procedures this week to complete the dosing phase of the study.
Following dosing, all subjects will enter a 63-day observation and sampling period.
Topline results expected by the end of 2019 or early in 2020.
Midatech is developing therapies using three novel delivery mechanisms.
MTD201 uses Q-Sphera, a polymer microsphere innovation used to prolong and control the release of therapeutics over an extended period of time -from weeks to months.
